Valeant Lifts Allergan Bid, Defends Business Model

By | May 28, 2014

Scalper1 News

Valeant Pharmaceuticals raised its hostile bid for fellow drugmaker Allergan Wednesday morning as the campaign increasingly turned into a debate about Valeant’s own business model. Investors seemed unimpressed as Valeant’s stock fell 2.3% to 126.95 while Allergan’s slid 5.4% to 156.12. Valeant (VRX) added $10 a share in cash to last month’s original offer of $48.30 plus 0.83 of a Valeant share for each Allergan (AGN) share, coming to a total of Scalper1 News

Scalper1 News